Only in Titles

           Search results for: Mouse Anti-Human IGF Antibodies    

paperclip

#30697600   // Save this To Up

The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels.

The antiaging protein Klotho is shed and released into the blood stream (soluble Klotho). Growth hormone (GH) is considered an active Klotho regulator, because growth retardation is described in Klotho-deficient mice. The origin of circulating Klotho is, however, not fully understood.

2638 related Products with: The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels.

FDA Standard Frozen Tissu FDA Standard Frozen Tissu Multiple organ cancer tis Normal rat multiple organ FDA Standard Frozen Tissu Multiple organ tumor tiss FDA Standard Frozen Tissu Normal rat multiple organ FDA Standard Frozen Tissu FDA Standard Frozen Tissu Normal mouse multiple org Normal rat multiple organ

Related Pathways

paperclip

#21942521   // Save this To Up

Evaluation of two ELISA methods to detect therapeutic anti-IGF1R antibodies in clinical study samples of dalotuzumab.

Dalotuzumab (MK 0646), an anti-IGF1R antibody intended for cancer therapy, has progressed to Phase III clinical trials. To evaluate pharmacokinetic properties, we developed and compared two ELISAs to measure dalotuzumab in human serum and validated the second method following regulatory guidelines for ligand-binding assays.

1417 related Products with: Evaluation of two ELISA methods to detect therapeutic anti-IGF1R antibodies in clinical study samples of dalotuzumab.

Rabbit Anti-Human Toll In FDA Standard Frozen Tissu Multiple organ tumor tiss Goat Anti-Human TOM1L1 SR FDA Standard Frozen Tissu Oral squamous cell cancer Goat Anti-Human PARK2, (i Rabbit Anti-Influenza A V Thyroid cancer tissue arr Goat Anti-Human FOXC1 (in Goat Anti- Neurogenin 1 ( Human normal bone and ost

Related Pathways

paperclip

#10650956   // Save this To Up

Enhancement of insulin-like growth factor I activity by novel antisera: potential structure/function interactions.

Insulin-like growth factor I (IGF-I) is essential for normal growth and development, regulating cell proliferation, differentiation, and survival. Little IGF-I exists in the free form; rather, it is bound to one of a family of six specific IGF-binding proteins (IGFBPs). Usually, IGFBPs have a high affinity for IGF-I and inhibit its activity. Intriguingly, some IGFBPs also potentiate IGF-I action; the precise mechanism of this is unclear, but it is thought to include modification of the IGFBP to lower its affinity for IGF-I. We have previously generated a novel antihuman (h) IGF-I antiserum that, instead of inhibiting IGF-I activity, enhances it in vivo. As the enhancing anti-IGF-I antiserum and potentiating IGFBPs share several properties with regard to IGF action, the antibody may provide a model for examining the actions of enhancing IGFBPs. In this study we demonstrate that the antiserum can also enhance IGF-I activity in vitro, assessed as cell number of a bovine fibroblast cell line, suggesting that its actions might not merely be confined to changing the kinetics of IGF-I clearance or degradation. Epitope scanning using overlapping octamer and hexamer peptides spanning the entire sequence of IGF-I indicates that the enhancing antiserum recognizes a specific linear region spanning the C-terminal region of the C domain and the proximal A domain (residues Ser33 to Cys47), and that this recognition is not present in nonenhancing antisera. Further, this region is located on the opposite surface of IGF-I from putative type 1 receptor-binding residues, allowing the possibility that the antiserum might be able to modulate IGF-I receptor binding. Antibodies raised against a synthetic peptide corresponding to Ser33 to Cys47 of IGF-I also potentiated IGF-I activity in vivo. As IGF-I may be beneficial in various clinical conditions associated with catabolism or cell repair, we suggest that this potentiating anti-IGF-I antiserum has favorable properties that could form a basis for therapeutic strategy.

1167 related Products with: Enhancement of insulin-like growth factor I activity by novel antisera: potential structure/function interactions.

Rat monoclonal anti mouse Mouse Anti-Insulin-Like G Mouse Insulin-like Growth IGF1, Insulin-like growth Mouse Insulin-like Growth Hamster anti mouse Insuli Human Insulin-like Growth Rat monoclonal anti mouse Human Insulin-like Growth Rat Insulin-like Growth F Rat monoclonal anti mouse Human Insulin-like Growth

Related Pathways